- Home
- GMAB vs GEN Comparison
GMAB vs GEN Comparison
Compare GMAB & GEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- GEN
- Stock Information
- Founded
- GMAB 1999
- GEN 1982
- Country
- GMAB Denmark
- GEN United States
- Employees
- GMAB N/A
- GEN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- GEN Computer Software: Prepackaged Software
- Sector
- GMAB Health Care
- GEN Technology
- Exchange
- GMAB Nasdaq
- GEN Nasdaq
- Market Cap
- GMAB 15.0B
- GEN 17.0B
- IPO Year
- GMAB N/A
- GEN N/A
- Fundamental
- Price
- GMAB $21.80
- GEN $27.32
- Analyst Decision
- GMAB Buy
- GEN Buy
- Analyst Count
- GMAB 8
- GEN 4
- Target Price
- GMAB $43.00
- GEN $28.75
- AVG Volume (30 Days)
- GMAB 1.1M
- GEN 3.1M
- Earning Date
- GMAB 02-12-2025
- GEN 01-30-2025
- Dividend Yield
- GMAB N/A
- GEN 1.82%
- EPS Growth
- GMAB 14.35
- GEN N/A
- EPS
- GMAB 10.80
- GEN 0.99
- Revenue
- GMAB $2,967,926,227.00
- GEN $3,863,000,000.00
- Revenue This Year
- GMAB $32.03
- GEN $3.93
- Revenue Next Year
- GMAB $16.97
- GEN $3.33
- P/E Ratio
- GMAB $19.02
- GEN $27.64
- Revenue Growth
- GMAB 17.75
- GEN 2.44
- 52 Week Low
- GMAB $19.85
- GEN $19.08
- 52 Week High
- GMAB $31.88
- GEN $31.72
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- GEN 40.98
- Support Level
- GMAB $19.89
- GEN $26.55
- Resistance Level
- GMAB $21.26
- GEN $27.96
- Average True Range (ATR)
- GMAB 0.42
- GEN 0.43
- MACD
- GMAB 0.02
- GEN 0.08
- Stochastic Oscillator
- GMAB 80.08
- GEN 54.61
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.